Peptide CDMO Market Size, Share, Growth, And Industry Analysis By Type (LPPS, SPPS, and Mixed Phase) By Application (Pharmaceutical Industry, Cosmetics Industry, and Others), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

PEPTIDE CDMO MARKET OVERVIEW

The global peptide cdmo market size is estimated at USD 5.51 Billion in 2026, set to expand to USD 29.15 Billion by 2035, growing at a CAGR of 20.3% during the forecast from 2026 to 2035.

The rising demand for peptide-based therapies has led to tremendous expansion in the Peptide CDMO market in recent years. Contract Development and Manufacturing Organizations (CDMOs) are essential in the peptide business since they offer knowledge and services for creating peptide pharmaceuticals. Generally, there are two types of peptide CDMOs: integrated CDMOs and freestanding CDMOs. Integrated CDMOs provide full-service solutions that cover the entire peptide drug development process, from discovery to commercialization.

These businesses have internal resources for formulation development, regulatory support, and peptide synthesis. Separate CDMOs focus on particular facets of peptide manufacture, like peptide synthesis or formulation development. They work with other CDMOs or pharmaceutical businesses to offer an extensive selection of services. The individual requirements of the drug development program will determine whether integrated or standalone CDMOs are the best option. When there is a need for seamless collaboration between various stages of drug development, integrated CDMOs are preferred. Standalone CDMOs can be easily included in the overall drug development process and are appropriate for initiatives that call for knowledge in a particular field.

KEY FINDINGS

COVID-19 IMPACT

Disrupted Supply Chains And Manufacturing Operations And The Lockdown Measures Hampered The Market Growth

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the Peptide CDMO market growth and demand returning to pre-pandemic levels once the pandemic is over.

The COVID-19 pandemic has significantly impacted this market. While the need for peptide-based therapies has grown, the pandemic has affected production processes and supply chains. The development and supply of peptide medications have been delayed due to the lockdown measures implemented by several nations. Additionally, resources and attention have been diverted from other therapeutic areas, such as peptides, due to the focus on COVID-19 therapies and vaccines. However, given the rising need for peptide-based treatments, this market's long-term prospects are still promising.

LATEST TRENDS

Increasing Adoption Of Automation And Digitalization In Peptide Manufacturing Fuels Boosts Market Expansion

The growing adoption of automation and digitalization in peptide manufacturing is one of the newest trends in the Peptide CDMO industry. Automation technologies, such as high-throughput peptide synthesizers and robotic systems, make it possible to produce peptides more quickly and effectively. Additionally, these technologies guarantee constant quality while lowering the possibility of human error. On the other side, digitization makes data-driven decision-making easier and enhances process control. CDMOs are better able to increase production, reduce costs, and hasten the development of peptide pharmaceuticals by incorporating automation and digitalization. The increased emphasis on individualized treatment is another new trend in the peptide CDMO industry. Due to their ability to be specifically designed to target particular disease pathways or patient populations, peptides offer special advantages in personalized therapeutics.

• According to the U.S. Food and Drug Administration (FDA), the use of peptides in therapeutic applications has grown by 20% in the last 5 years, with a marked increase in the approval of peptide-based drugs for cancer and diabetes.

• According to the European Medicines Agency (EMA), peptide drugs accounted for approximately 12% of all new drug approvals in Europe in 2023, signaling a growing interest in peptide therapies across various medical fields.

Download Free Sample to learn more about this report

PEPTIDE CDMO MARKET SEGMENTATION

By Type

The Peptide CDMO market can be segmented into LPPS, SPPS, and mixed phase. Among these, the LPPS is projected to experience rapid growth through 2035.

By Application

The market can be divided based on application into pharmaceutical industry, cosmetics industry, and others. The pharmaceutical industry is expected to hold the most Peptide CDMO market share in the upcoming years.

DRIVING FACTORS

Increasing Prevalence Of Chronic Diseases And The Need For More Effective Treatment Options Propels Market Expansion

More effective treatment options and the rising frequency of chronic diseases are needed. The capacity to target intracellular pathways, great specificity, and minimal toxicity of peptide-based therapies are only a few benefits. As a result, peptide medications are increasingly in demand across a range of therapeutic fields, including oncology, cardiovascular disease, and metabolic disorders. Through the provision of knowledge in the development and production of peptide drugs, CDMOs play a crucial part in satisfying this demand.

Rising Investment In Biopharmaceutical Research And Development Fuels Market Growth

A growing amount of money is being invested in biopharmaceutical research and development. Biologics, particularly peptides, are receiving more attention from the pharmaceutical sector because they have distinctive therapeutic possibilities. More specialized manufacturing skills are now required due to increased investment in developing peptide-based medicines. CDMOs are well-positioned to assist biopharmaceutical businesses in developing and producing peptide therapeutics because of their knowledge and infrastructure. This market is anticipated to increase in the upcoming years due to the partnership between CDMOs and pharmaceutical firms.

• According to the U.S. National Institutes of Health (NIH), the global research funding for peptide-based therapies in cancer and metabolic diseases has increased by 25% since 2020, accelerating the demand for peptide manufacturing services.

• According to the World Health Organization (WHO), the global burden of chronic diseases, including cancer and diabetes, which accounted for over 70% of global deaths in 2022, is driving the need for peptide-based drugs and CDMO services to support their production.

RESTRAINING FACTOR

Complexity And Cost Of Peptide Manufacturing And Regulatory Challenges Hinder Market Growth

Although this market is expected to increase, several considerations must be considered. The difficulty and expense of peptide production is one of the key obstacles. Inherently more difficult to produce than tiny molecules, peptides call for particular tools and knowledge. Effective and scalable production procedures are essential to address the rising demand for peptide pharmaceuticals. Furthermore, the price of producing peptides might be significant, which restricts the availability of peptide-based medicines in particular areas. Regulatory issues also constrain this market. Peptide medications must adhere to strict regulatory standards, which include quality assurance, analytical testing, and documentation.

• According to the U.S. Food and Drug Administration (FDA), peptide manufacturing processes face regulatory challenges, with 40% of peptide-based drug applications experiencing delays due to the complexity of their production processes.

• According to the European Commission, the high cost of raw materials and the need for specialized equipment for peptide synthesis have resulted in a 15-20% increase in production costs for CDMOs in the past 2 years, limiting the market's growth potential.

• Download Free Sample to learn more about this report

•  

PEPTIDE CDMO MARKET REGIONAL INSIGHTS

North America To Dominate Market Due To The Increasing Prevalence Of Chronic Diseases And The Need For More Effective Treatment Options

The U.S. holds the Peptide CDMO market share, and factors driving the market growth in this region include the increasing prevalence of chronic diseases and the need for more effective treatment options. The rising incidence of chronic illnesses and the requirement for more efficient treatment alternatives. The benefits of peptide-based therapies are high specificity, low toxicity, and the capacity to target intracellular circuits. Due to this, there is an increasing need for peptide medications in many therapeutic fields, including oncology, cardiovascular illness, and metabolic disorders. CDMOs play a crucial part in satisfying this demand by offering knowledge in peptide drug research and production.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios

• According to PolyPeptide, the company has expanded its global peptide production facilities by 25% in 2023 to meet the increasing demand for custom peptides and biologics across pharmaceuticals and biotechnology.

• According to Thermo Fisher Pharma, the company has increased its peptide manufacturing capacity by 30% in 2023, particularly focusing on peptides for oncology and metabolic disorder treatments, and is one of the top global players in GMP peptide production.

List of Top Peptide CDMO Companies

• Chengdu Shengnuo Biotechnology Co., Ltd (China)
• Jiangsu Nuotai Ao Nuo Biopharmaceutical Co., Ltd (China)
• PolyPeptide (Sweden)
• Thermo Fisher Pharma (U.S.)
• Biopeptek (U.S.)
• Alabiochem (China)
• ScinoPharm (Taiwan)
• CordenPharma (Switzerland)
• Piramal Pharma (India)
• Space Peptides (Australia)
• Bachem (Switzerland)
• Provepharm (France)
• CPC SCIENTIFIC (U.S.)
• CBL (China)
• Alpha Biophama (U.S.)
• AmbioPharm (U.S.)
• Aurigene Pharmaceutical Services (India)

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.